Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sigmoid Neoplasms | 1 | 2022 | 2 | 0.780 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 51 | 0.740 |
Why?
|
| Pulpitis | 1 | 2022 | 1 | 0.740 |
Why?
|
| MicroRNAs | 1 | 2022 | 397 | 0.550 |
Why?
|
| Stomach Neoplasms | 5 | 2021 | 207 | 0.480 |
Why?
|
| Prognosis | 6 | 2022 | 2118 | 0.250 |
Why?
|
| Hyperuricemia | 2 | 2016 | 6 | 0.240 |
Why?
|
| Uric Acid | 2 | 2016 | 23 | 0.240 |
Why?
|
| Hyperkalemia | 1 | 2025 | 12 | 0.230 |
Why?
|
| Proton Therapy | 1 | 2024 | 12 | 0.220 |
Why?
|
| Renal Dialysis | 1 | 2025 | 196 | 0.200 |
Why?
|
| Uveitis | 1 | 2023 | 24 | 0.200 |
Why?
|
| Genes, Regulator | 1 | 2022 | 5 | 0.200 |
Why?
|
| Methyltransferases | 1 | 2022 | 28 | 0.190 |
Why?
|
| Gastroesophageal Reflux | 1 | 2023 | 51 | 0.190 |
Why?
|
| Methylation | 1 | 2022 | 127 | 0.190 |
Why?
|
| Dental Pulp | 1 | 2022 | 3 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2022 | 38 | 0.180 |
Why?
|
| Interleukin-1beta | 1 | 2022 | 88 | 0.170 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 203 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2021 | 717 | 0.160 |
Why?
|
| Neutrophils | 1 | 2021 | 153 | 0.150 |
Why?
|
| Neoplasms, Gonadal Tissue | 1 | 2019 | 1 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 113 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 3494 | 0.150 |
Why?
|
| Teratoma | 1 | 2019 | 22 | 0.150 |
Why?
|
| Humans | 15 | 2025 | 53230 | 0.150 |
Why?
|
| Behavior | 1 | 2018 | 46 | 0.140 |
Why?
|
| Text Messaging | 1 | 2018 | 23 | 0.140 |
Why?
|
| Cells, Cultured | 1 | 2022 | 1569 | 0.140 |
Why?
|
| Self Care | 1 | 2018 | 136 | 0.130 |
Why?
|
| Vital Capacity | 1 | 2017 | 16 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2018 | 136 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 187 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 405 | 0.130 |
Why?
|
| Young Adult | 8 | 2021 | 4511 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2016 | 18 | 0.130 |
Why?
|
| Fever | 1 | 2017 | 112 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 44 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2018 | 325 | 0.120 |
Why?
|
| Aged | 9 | 2025 | 10429 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 132 | 0.120 |
Why?
|
| Middle Aged | 10 | 2025 | 13419 | 0.120 |
Why?
|
| China | 3 | 2025 | 135 | 0.110 |
Why?
|
| Prevalence | 3 | 2025 | 1034 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2016 | 252 | 0.110 |
Why?
|
| Neoplasms | 1 | 2024 | 1334 | 0.110 |
Why?
|
| Adult | 9 | 2025 | 14534 | 0.100 |
Why?
|
| Lung | 1 | 2017 | 481 | 0.100 |
Why?
|
| Heart Failure | 1 | 2018 | 531 | 0.100 |
Why?
|
| Male | 10 | 2025 | 27435 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 1232 | 0.080 |
Why?
|
| Female | 10 | 2025 | 28782 | 0.080 |
Why?
|
| Survival Rate | 3 | 2017 | 949 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 501 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1099 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2021 | 659 | 0.070 |
Why?
|
| Incidence | 2 | 2023 | 1085 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 186 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 262 | 0.060 |
Why?
|
| Gastrectomy | 2 | 2017 | 73 | 0.060 |
Why?
|
| Adolescent | 4 | 2019 | 6907 | 0.060 |
Why?
|
| Potassium | 1 | 2025 | 53 | 0.060 |
Why?
|
| Heavy Ion Radiotherapy | 1 | 2024 | 2 | 0.050 |
Why?
|
| Radiation Oncology | 1 | 2024 | 26 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 774 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 249 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2023 | 93 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2023 | 67 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2318 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2024 | 181 | 0.050 |
Why?
|
| Risk Factors | 2 | 2025 | 4017 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 250 | 0.050 |
Why?
|
| Computational Biology | 1 | 2023 | 209 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 20 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2018 | 6819 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 35 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 175 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 106 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2018 | 30 | 0.040 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 2017 | 1 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 47 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1557 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 132 | 0.030 |
Why?
|
| Hematocrit | 1 | 2016 | 40 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 36 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 211 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 52 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 161 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 391 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 171 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 598 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 241 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1136 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 747 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 518 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2015 | 490 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1212 | 0.020 |
Why?
|
| Smoking | 1 | 2015 | 526 | 0.020 |
Why?
|
| Infant | 1 | 2019 | 3805 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 4162 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1723 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5595 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 86 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 42 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 107 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2008 | 174 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 232 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 228 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2008 | 94 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 1204 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 670 | 0.020 |
Why?
|
| Child | 1 | 2019 | 7379 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 289 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 1016 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 975 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 5982 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 13526 | 0.010 |
Why?
|